[go: up one dir, main page]

DK1439175T3 - Pyrimidinforbindelse og medicinsk sammensætning indeholdende denne - Google Patents

Pyrimidinforbindelse og medicinsk sammensætning indeholdende denne

Info

Publication number
DK1439175T3
DK1439175T3 DK02802050.1T DK02802050T DK1439175T3 DK 1439175 T3 DK1439175 T3 DK 1439175T3 DK 02802050 T DK02802050 T DK 02802050T DK 1439175 T3 DK1439175 T3 DK 1439175T3
Authority
DK
Denmark
Prior art keywords
substituted
group
carbon atoms
aromatic heterocyclic
atom
Prior art date
Application number
DK02802050.1T
Other languages
English (en)
Inventor
Hitoshi Harada
Osamu Asano
Masato Ueda
Shuhei Miyazawa
Yoshihiko Kotake
Yasuhiro Kabasawa
Masahiro Yasuda
Nobuyuki Yasuda
Daisuke Iida
Junichi Nagakawa
Kazuo Hirota
Makoto Nakagawa
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of DK1439175T3 publication Critical patent/DK1439175T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK02802050.1T 2001-10-22 2002-10-22 Pyrimidinforbindelse og medicinsk sammensætning indeholdende denne DK1439175T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001324018 2001-10-22
PCT/JP2002/010952 WO2003035639A1 (fr) 2001-10-22 2002-10-22 Compose de pyrimidine et composition medicinale contenant ledit compose

Publications (1)

Publication Number Publication Date
DK1439175T3 true DK1439175T3 (da) 2011-07-18

Family

ID=19140824

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02802050.1T DK1439175T3 (da) 2001-10-22 2002-10-22 Pyrimidinforbindelse og medicinsk sammensætning indeholdende denne

Country Status (24)

Country Link
US (2) US7396836B2 (da)
EP (2) EP2246344A1 (da)
JP (1) JP4462930B2 (da)
KR (1) KR100884025B1 (da)
CN (1) CN100519549C (da)
AT (1) ATE507217T1 (da)
AU (1) AU2002335536B2 (da)
BR (1) BR0213455A (da)
CA (1) CA2463284C (da)
CY (1) CY1112341T1 (da)
DE (1) DE60239884D1 (da)
DK (1) DK1439175T3 (da)
ES (1) ES2364328T3 (da)
HU (1) HUP0401950A3 (da)
IL (2) IL161493A0 (da)
MX (1) MXPA04003795A (da)
NO (1) NO327581B1 (da)
NZ (1) NZ532373A (da)
PL (1) PL215572B1 (da)
PT (1) PT1439175E (da)
RU (1) RU2288227C2 (da)
TW (1) TWI330183B (da)
WO (1) WO2003035639A1 (da)
ZA (1) ZA200402898B (da)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI330183B (da) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
AU2002950853A0 (en) * 2002-08-19 2002-09-12 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compound and pharmaceutical use thereof
ES2229928B1 (es) * 2003-10-02 2006-07-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirimidin-2-amina.
GB0323138D0 (en) * 2003-10-03 2003-11-05 Chang Lisa C W Pyrimidines substituted in the 2,4,6 positions and their different uses
GB0323137D0 (en) * 2003-10-03 2003-11-05 Chang Lisa C W 2,4,6- Trisubstituted pyrimidines and their different uses
EP1679309A4 (en) * 2003-10-24 2007-03-28 Ono Pharmaceutical Co ANTISTRESS MEDICAMENT AND ITS MEDICAL USE
BRPI0415863A (pt) * 2003-10-27 2007-01-09 Astellas Pharma Inc derivados pirazina e seus usos farmacêuticos
JP2007514003A (ja) * 2003-12-15 2007-05-31 アルミラル プロデスファルマ アーゲー アデノシン受容体アンタゴニストとしての２，６−ビスヘテロアリール−４−アミノピリミジン
HUE025659T2 (en) 2003-12-26 2016-04-28 Kyowa Hakko Kirin Co Ltd Thiazole derivatives
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
CA2562244A1 (en) * 2004-04-07 2005-10-27 Takeda Pharmaceutical Company Limited Cyclic compounds
GB2416125A (en) * 2004-07-15 2006-01-18 Michael James Hill Device for supplying fluid to an ear
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
GB0428514D0 (en) * 2004-12-31 2005-02-09 Prosidion Ltd Compounds
AU2006225699B2 (en) * 2005-03-21 2011-02-24 Eisai R & D Management Co., Ltd. Crystal of 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1- methylpyridin-2(1H)-one and process for producing the same
US7538117B2 (en) 2005-03-21 2009-05-26 Eisai R&D Management Co., Ltd. Crystalline and amorphous pyrimidine compounds and processes for preparing pyrimidine compounds
US7396928B2 (en) 2005-03-21 2008-07-08 Eisai R&D Management Co., Ltd. Crystals of 5-[2-amino-4-(2-furyl) pyrimidin-5-yl]-1-methylpyridin-2(1H)-one and processes for preparing the same
US20080275064A1 (en) * 2005-04-11 2008-11-06 Deborah Slee Substituted Pyrimidines as Adenosine Receptor Antagonists
SI1928454T1 (sl) 2005-05-10 2015-01-30 Intermune, Inc. Piridonski derivati za moduliranje s stresom aktiviranega protein kinaznega sistema
WO2006137527A1 (ja) 2005-06-23 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. チアゾール誘導体
ES2270715B1 (es) * 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
PT1921077T (pt) 2005-08-02 2017-10-26 Kyowa Hakko Kirin Co Ltd Agente para tratar e/ou prevenir distúrbio do sono
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
AU2007221049A1 (en) * 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
DK2004654T3 (da) 2006-04-04 2013-07-22 Univ California Pyrazolopyrimidin derivater til anvendelse som kinase antagonister
US20080009623A1 (en) * 2006-07-06 2008-01-10 Eisai R&D Management Co., Ltd. Pyrimidine compounds
JP2009286694A (ja) * 2006-09-07 2009-12-10 Eisai R & D Management Co Ltd ５−［２−アミノ−４−（２−フリル）ピリミジン−５−イル］−１−メチルピリジン−２（１ｈ）−オンの塩およびそれらの結晶
ES2303776B1 (es) * 2006-12-29 2009-08-07 Laboratorios Almirall S.A. Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b.
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
EP2173722B1 (en) * 2007-07-26 2012-08-29 Novartis AG Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
CN103342695B (zh) 2007-09-14 2015-04-22 杨森制药有限公司 1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮
WO2009046448A1 (en) * 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
KR101897881B1 (ko) 2008-01-04 2018-09-12 인텔리카인, 엘엘씨 특정 화학 물질, 조성물 및 방법
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
EP2252293B1 (en) 2008-03-14 2018-06-27 Intellikine, LLC Kinase inhibitors and methods of use
JP5460690B2 (ja) 2008-03-26 2014-04-02 アドヴィナス・セラピューティックス・リミテッド アデノシンレセプターアンタゴニストとしてのヘテロ環化合物
WO2009149188A1 (en) 2008-06-03 2009-12-10 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
CN101343253B (zh) * 2008-06-24 2011-03-16 陕西师范大学 2-氨基-4,5-二芳基嘧啶类化合物及其制备方法和药物用途
WO2010006072A2 (en) * 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
AU2009268611B2 (en) 2008-07-08 2015-04-09 Intellikine, Llc Kinase inhibitors and methods of use
WO2010025890A1 (en) 2008-09-02 2010-03-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
DK2358720T3 (da) 2008-10-16 2016-06-06 Univ California Heteroarylkinaseinhibitorer med kondenseret ring
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
EP2373649B1 (en) 2008-11-28 2013-01-23 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
AU2010222289B2 (en) 2009-03-13 2013-07-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
CA2760791C (en) 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
AU2010246609B2 (en) 2009-05-12 2013-09-05 Addex Pharma S.A. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MX2011011962A (es) 2009-05-12 2012-02-28 Janssen Pharmaceuticals Inc Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostericos positivos de receptores de glutamato metabotropico (mglur2).
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
WO2011055391A1 (en) 2009-11-09 2011-05-12 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
BR112012021659A2 (pt) 2010-03-04 2018-01-30 Merck Sharp & Dohme composto, composição farmacêutica, método para tratar e/ou prevenir distúrbios e doenças.
ES2365960B1 (es) * 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
ES2593256T3 (es) 2010-05-21 2016-12-07 Infinity Pharmaceuticals, Inc. Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
CA2810625C (en) 2010-09-13 2018-01-23 Advinus Therapeutics Private Limited Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2618666A4 (en) * 2010-09-24 2014-04-16 N30 Pharmaceuticals Inc NEW DIHYDROPYRIMIDIN-2 (1H) -ON COMPOUNDS AS NEUROKININ-3 RECEPTOR ANTAGONISTS
WO2012062750A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3581574A1 (en) 2011-01-10 2019-12-18 Infinity Pharmaceuticals, Inc. A composition for oral administration for use in the treatment of cancer, an inflammatory disease or an auto-immune disease
WO2012148540A1 (en) 2011-02-23 2012-11-01 Intellikine, Llc Combination of kanase inhibitors and uses threof
CZ305457B6 (cs) * 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
JP6027611B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
CN103998442B (zh) 2011-08-29 2016-09-14 无限药品股份有限公司 杂环化合物及其用途
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
JP6068515B2 (ja) 2012-03-01 2017-01-25 アレイ バイオファーマ、インコーポレイテッド セリン／トレオニンキナーゼ阻害剤
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CN104995192A (zh) 2012-09-26 2015-10-21 加利福尼亚大学董事会 Ire1的调节
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
NZ708563A (en) 2012-11-01 2019-02-22 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
EP2922543B1 (en) * 2012-11-20 2017-05-24 Merck Sharp & Dohme Corp. Substituted pyridone derivatives as pde10 inhibitors
KR101529496B1 (ko) * 2012-12-27 2015-06-22 한국과학기술원 낮은 열팽창 계수를 갖는 신규한 폴리아미드이미드
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
HUE045610T2 (hu) 2014-01-21 2020-01-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk
SMT202100103T1 (it) 2014-01-21 2021-03-15 Janssen Pharmaceutica Nv Combinazione comprendente modulatori allosterici postivi del recettore glutammatergico metabotropico sottotipo 2 e loro utilizzo
CN105829298B (zh) 2014-02-14 2019-02-01 四川海思科制药有限公司 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
JP6701088B2 (ja) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物
MX2016012808A (es) 2014-04-02 2017-01-05 Intermune Inc Piridinonas anti-fibroticas.
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3350183B1 (en) 2015-09-14 2025-04-02 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
JP2017149663A (ja) * 2016-02-24 2017-08-31 株式会社Ｌｔｔバイオファーマ 過敏性腸症候群治療剤
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
BR112018077021A2 (pt) 2016-06-24 2019-04-02 Infinity Pharmaceuticals, Inc. terapias de combinação
KR102611446B1 (ko) * 2017-01-20 2023-12-06 아르커스 바이오사이언시즈 인코포레이티드 암-관련 장애의 치료를 위한 아졸로피리미딘
CN110446712B (zh) * 2017-04-07 2021-09-14 南京明德新药研发有限公司 作为A2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物
WO2018204661A1 (en) * 2017-05-05 2018-11-08 Arcus Biosciences, Inc. Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
US11478479B2 (en) 2018-02-16 2022-10-25 Arcus Biosciences, Inc. Dosing with an azolopyrimidine compound
CN110240593A (zh) * 2018-03-09 2019-09-17 四川科伦博泰生物医药股份有限公司 取代芳胺化合物及其制备方法和用途
CN108314631A (zh) * 2018-04-19 2018-07-24 中国科学院昆明植物研究所 二芳基乙烯类化合物及其药物组合物和其应用
CN110655509B (zh) * 2018-06-29 2023-01-24 江苏恒瑞医药股份有限公司 2-胺基嘧啶类衍生物、其制备方法及其在医药上的应用
CN110684020B (zh) * 2018-07-05 2023-01-20 江苏恒瑞医药股份有限公司 2-胺基嘧啶类衍生物、其制备方法及其在医药上的应用
WO2020014332A1 (en) * 2018-07-10 2020-01-16 Nikang Therapeutics, Inc. Adenosine receptor binding compounds
CN111094254B (zh) * 2018-07-12 2022-07-26 江苏恒瑞医药股份有限公司 杂芳基类衍生物、其制备方法及其在医药上的应用
WO2020135195A1 (zh) 2018-12-28 2020-07-02 四川科伦博泰生物医药股份有限公司 氨基吡啶类化合物及其制备方法和用途
CN111377873B (zh) * 2018-12-28 2023-03-28 四川科伦博泰生物医药股份有限公司 氨基嘧啶化合物及其制备方法和用途
KR20210110288A (ko) * 2018-12-28 2021-09-07 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 치환된 아릴 화합물, 및 이의 제조 방법 및 이의 용도
US10689374B1 (en) 2019-07-12 2020-06-23 United Arab Emirates University Pyrimidine-thiazolidinone derivatives
US10702525B1 (en) 2019-09-04 2020-07-07 United Arab Emirates University Pyrimidine derivatives as anti-diabetic agents
AU2021239135B2 (en) * 2020-03-16 2024-05-02 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Substituted pyrimidine or pyridine amine derivative, composition thereof, and medical use thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3029426A1 (de) * 1980-08-02 1982-03-11 Bayer Ag, 5090 Leverkusen Gegen zwecken wirksame pour-on-formulierungen
US4725600A (en) 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
FR2584925B1 (fr) * 1985-07-17 1987-11-27 Bosserelle Micheline Composition de corps gras d'origine vegetale pour usage cosmetique
US4927813A (en) * 1988-03-08 1990-05-22 Bernstein Joel E Method and composition for treating pediculosis capitis
JPH0252360A (ja) 1988-08-15 1990-02-21 Fujitsu Ltd 電子写真感光体
US5362634A (en) * 1989-10-30 1994-11-08 Dowelanco Process for producing A83543 compounds
OA09249A (fr) * 1988-12-19 1992-06-30 Lilly Co Eli Composés de macrolides.
US5288483A (en) * 1990-04-18 1994-02-22 The Procter & Gamble Company Anti-lice treatment compositions
DD294255A5 (de) * 1990-05-14 1991-09-26 Adw Forschungsstelle Fuer Chemische Toxikologie,De Verfahren zur herstellung tetrazolylsubstituierter pyrimidinderivate
US5227163A (en) * 1991-01-18 1993-07-13 Clilco, Ltd. Lice-repellant compositions
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5539089A (en) * 1991-11-08 1996-07-23 Dowelanco A83543 aglycones and pseudoglycones
US5227295A (en) * 1991-11-08 1993-07-13 Dowelanco Process for isolating A83543 and its components
US5202242A (en) * 1991-11-08 1993-04-13 Dowelanco A83543 compounds and processes for production thereof
JP2613355B2 (ja) 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
US5591606A (en) * 1992-11-06 1997-01-07 Dowelanco Process for the production of A83543 compounds with Saccharopolyspora spinosa
EP0688332B1 (en) * 1993-03-12 1997-03-26 Dowelanco New a83543 compounds and process for production thereof
US5795905A (en) * 1995-06-06 1998-08-18 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
US5935966A (en) * 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
EP0888335A4 (en) * 1996-03-13 2002-01-02 Smithkline Beecham Corp NEW PYRIMIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CYTOKININ MEDIATOR DISEASES
US6010710A (en) * 1996-03-29 2000-01-04 Merial Direct pour-on skin solution for antiparasitic use in cattle and sheep
US5952331A (en) * 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
US6001981A (en) * 1996-06-13 1999-12-14 Dow Agrosciences Llc Synthetic modification of Spinosyn compounds
FR2756177B1 (fr) * 1996-11-28 1999-01-29 Oreal Dispersion aqueuse de vesicules resistantes a la deshydratation
HUP0001140A3 (en) 1996-12-05 2002-05-28 Amgen Inc Thousand Oaks Substituted pyrimidinone and pyridone compounds and methods of use
CN1246858A (zh) * 1996-12-05 2000-03-08 安姆根有限公司 取代的嘧啶化合物和它们的应用
TW520362B (en) * 1996-12-05 2003-02-11 Amgen Inc Substituted pyrimidine compounds and pharmaceutical composition comprising same
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US5880076A (en) * 1997-08-04 1999-03-09 Lever Brothers Company, Division Of Conopco, Inc. Compositions comprising glycacarbamate and glycaurea compounds
US6096326A (en) * 1997-08-15 2000-08-01 Scandinavian-American Import/Export Corporation Skin care compositions and use
JPH11188484A (ja) 1997-12-25 1999-07-13 Nkk Corp 多段研削バリ取り装置
JP3990061B2 (ja) 1998-01-05 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 プリン誘導体および糖尿病の予防・治療剤としてのアデノシンａ２受容体拮抗剤
USRE39112E1 (en) * 1998-01-05 2006-05-30 Eisai Co., Ltd. Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes
US6235754B1 (en) * 1998-01-30 2001-05-22 American Cyanamid Company Methods and compositions for protecting animals and humans against attack and infestation by arthropod and helminth parasites
DE19823397B4 (de) * 1998-05-26 2011-07-28 Bayer CropScience AG, 40789 Verwendung von Spinosynen zum Einsatz als Bodeninsektizide
AU4956699A (en) * 1998-06-19 2000-01-05 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
UA65624C2 (uk) * 1998-07-02 2004-04-15 Елі Ліллі Енд Компані Препарат для догляду за волоссям (варіанти) та спосіб боротьби з педикульозним ураженням людини із застосуванням спінозину (варіанти)
TWI241298B (en) 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
JP2000126489A (ja) 1998-10-21 2000-05-09 Purotonikusu Kenkyusho:Kk 糸又は布と接触するミシン用部品
ATE303387T1 (de) 1999-07-02 2005-09-15 Eisai Co Ltd Kondensierte imidazolderivate und arzneimittel gegen diabetes mellitus
RU2277911C2 (ru) * 2000-02-25 2006-06-20 Ф.Хоффманн-Ля Рош Аг Модуляторы аденозиновых рецепторов
AU2001248365A1 (en) 2000-03-23 2001-10-03 Mitsubishi Pharma Corporation 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives
EP1136482A1 (en) 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
EP1136486A1 (en) 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-[Indanylamino]pyrimidone and 2-[tetrahydronaphthalenylamino]pyrimidone derivatives
US7189717B2 (en) * 2000-04-26 2007-03-13 Eisai Co., Ltd. Medicinal compositions promoting bowel movement
AU7774101A (en) 2000-08-11 2002-02-25 Eisai Co Ltd 2-aminopyridine compounds and use thereof as drugs
KR100860827B1 (ko) * 2000-09-06 2008-09-30 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 글리코겐 합성효소 키나아제 3의 억제제
JP4105949B2 (ja) * 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
WO2002024893A2 (en) 2000-09-19 2002-03-28 Chiron Corporation CHARACTERIZATION OF THE GSK-3β PROTEIN AND METHODS OF USE THEREOF
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
TWI301834B (en) 2001-10-22 2008-10-11 Eisai R&D Man Co Ltd Pyrimidone compound and pharmaceutical composition including the same
TWI330183B (da) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
AU2002950853A0 (en) 2002-08-19 2002-09-12 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compound and pharmaceutical use thereof
US7538117B2 (en) 2005-03-21 2009-05-26 Eisai R&D Management Co., Ltd. Crystalline and amorphous pyrimidine compounds and processes for preparing pyrimidine compounds
US7396928B2 (en) 2005-03-21 2008-07-08 Eisai R&D Management Co., Ltd. Crystals of 5-[2-amino-4-(2-furyl) pyrimidin-5-yl]-1-methylpyridin-2(1H)-one and processes for preparing the same

Also Published As

Publication number Publication date
BR0213455A (pt) 2004-10-19
RU2288227C2 (ru) 2006-11-27
US20090030023A1 (en) 2009-01-29
HUP0401950A2 (hu) 2005-01-28
CA2463284C (en) 2010-10-19
EP1439175B1 (en) 2011-04-27
ES2364328T3 (es) 2011-08-31
NO327581B1 (no) 2009-08-24
US7396836B2 (en) 2008-07-08
MXPA04003795A (es) 2004-07-30
EP1439175A1 (en) 2004-07-21
KR20040053191A (ko) 2004-06-23
KR100884025B1 (ko) 2009-02-17
DE60239884D1 (de) 2011-06-09
IL161493A (en) 2010-04-29
TWI330183B (da) 2010-09-11
PL215572B1 (pl) 2013-12-31
JPWO2003035639A1 (ja) 2005-02-10
EP1439175A4 (en) 2004-12-29
PT1439175E (pt) 2011-07-08
NZ532373A (en) 2007-02-23
NO20041580L (no) 2004-07-22
CN1575290A (zh) 2005-02-02
US20050004149A1 (en) 2005-01-06
ZA200402898B (en) 2006-03-29
WO2003035639A1 (fr) 2003-05-01
IL161493A0 (en) 2004-09-27
CY1112341T1 (el) 2015-12-09
CN100519549C (zh) 2009-07-29
PL370274A1 (en) 2005-05-16
JP4462930B2 (ja) 2010-05-12
RU2004115495A (ru) 2005-04-10
CA2463284A1 (en) 2003-05-01
ATE507217T1 (de) 2011-05-15
HUP0401950A3 (en) 2010-06-28
EP2246344A1 (en) 2010-11-03
AU2002335536B2 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
DK1439175T3 (da) Pyrimidinforbindelse og medicinsk sammensætning indeholdende denne
NO20030637D0 (no) 2-aminopyridinforbindelser og anvendelse derav som legemidler
NO179675C (no) Pyrimidin-nukleosidderivater og farmasöytisk preparat inneholdende disse
TW200716528A (en) Cyclopropanecarboxamide derivatives
DE69833036D1 (de) Sulfonylderivate
BR0111230A (pt) Composto, e, uso e processo para a preparação do mesmo
ES2051772T3 (es) 2-sustituido-e-fusionado-(1,2,4)-triazol(1,5-c)pirimidinas, composiciones farmaceuticas y sus usos.
CA2312994A1 (en) Fungicide mixtures based on pyridine amides and chlorothalonil
DK1961734T3 (da) Aminforbindelse og anvendelse deraf til medicinske formål
WO2003028459A8 (de) Nicotinsäure-heterocyclyl-amide und analogue pyrimidin-derivate als schädlingsbekämpfungsmittel
EA200971061A1 (ru) Пиримидоновые соединения гетероариламидов
IL154709A0 (en) Pyridazinone and triazinone derivatives and pharmaceutical compositions containing the same
WO1999031981A3 (de) Fungizide mischungen auf der basis von pyridincarboxamiden
TW200613297A (en) Pyrazole derivatives
EP1775289A4 (en) NEW IMIDAZOLIDINE DERIVATIVES
EA200971060A1 (ru) Гетероариламидные пиримидоновые производные
WO2005011697A3 (en) Sulfonamide derivatives with activity on protein kinase a and b
KR970069989A (ko) 피리딘-2,3-디카르복실산 디아미드 유도체 및 유효성분으로 상기 유도체를 함유하는 제초제
KR930023031A (ko) 아졸 유도체를 함유하는 항아로마타제제
HUP0000366A2 (hu) Eljárás heterociklusos vegyületek előállítására
PT1492792E (pt) Derivados de 3-heteroaril-3,5-di-hidro-4-oxo-4h-piridazino(4, 5-b) ao em terapeutica.
NO20055530L (no) NK-2-antagonistiske basiske lineaere forbindelser og preparater som inneholder dem
ATE500241T1 (de) Phenyl- und pyridyl-piperidine mit tnf-wirkung
TH85134A (th) อนุพันธ์ไอโซอินโดลีนต่าง ๆ
ATE66000T1 (de) Heterocyclische herbizide.